Monday, May 20, 7:15 a.m. - 8:15 a.m.

Educational Symposium

In December of 2018, the FDA released a new strategic framework to advance the use of real-world evidence (RWE) to support the development of drugs and biologics. The framework serves as the FDA’s roadmap for more fully incorporating real-world data (RWD) and RWE, with the ultimate goal of developing a clear path to ensure RWE solutions are part of drug development and regulatory life cycles.

So how does this framework impact biopharma manufacturers current and future drug development plans? How does this impact current RWE approaches for generating data on safety and effectiveness? And what does this mean for the future of clinical trials? Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, explores the implications of this framework with key experts across the healthcare continuum.

Podium Presentation

Join Andrew Klink PhD, MPH, Director of Real-World Evidence & Insights, as he presents results of a study aimed to assess community rheumatologists’ experience with and perceptions of non-medical switching between originator biologics and their biosimilars in routine clinical practice.

BREAKOUT SESSION 8
P16: TREATMENT PATTERNS
Wednesday, May 22, 8:30 a.m. - 9:30 a.m.

Click here to view the full programming schedule and details at ISPOR 2019.

Presented by:

Bruce Feinberg
DO, Vice President & Chief Medical Officer

Presented by:

Andrew Klink
PhD, MPH, Director of Real-World Evidence & Insights

ISPOR 2019

Meet with our experts at ISPOR.

Cardinal Health Real-World Evidence & Insights presents

21st century FDA – Exploring the rise of real-world evidence

Monday, May 20, 7:15 a.m. - 8:15 a.m.